New Antifungal Drugs Target Resistant Fungal Infections

Why Are New Antifungal Drugs Needed Now?

The World Health Organization's fungal priority pathogens list identified 19 fungal pathogens that need greater research and public health attention, including Candida auris, Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans in the highest-priority group. These organisms matter clinically because they can cause bloodstream infection, pneumonia, meningitis or disseminated disease in people with weakened immune systems, cancer therapy, organ transplantation, intensive care exposure or invasive medical devices.

Antifungal drug development is difficult because fungi and humans are both eukaryotic, which leaves fewer drug targets that can kill the pathogen without harming the patient. Clinicians still rely heavily on a small number of major antifungal classes, including azoles, echinocandins and amphotericin B formulations, so resistance can quickly narrow practical treatment choices.

Which Antifungal Treatment Advances Are Changing Care?

Rezafungin, approved by the U.S. Food and Drug Administration in 2023 for adults with candidemia and invasive candidiasis when limited or no alternative options are available, is a newer echinocandin designed for once-weekly dosing. Like other echinocandins, it inhibits beta-1,3-D-glucan synthesis, weakening the fungal cell wall; the longer dosing interval may help selected hospitalized patients and treatment-transition planning.

Ibrexafungerp is another cell-wall-active antifungal, approved for vulvovaginal candidiasis and reduction of recurrent vulvovaginal candidiasis in some patients. Beyond approved drugs, investigational agents such as fosmanogepix and olorofim are being studied because they target fungal biology differently from older azoles and polyenes, a key strategy when resistance or toxicity limits standard therapy.

How Can Better Diagnosis Improve Fungal Infection Outcomes?

Diagnosis remains one of the largest gaps in fungal medicine. Blood cultures can miss some invasive fungal infections, symptoms often overlap with bacterial sepsis or pneumonia, and species-level identification is essential because Candida auris, Candida glabrata and Aspergillus species may differ substantially in drug susceptibility.

Modern laboratory tools, including MALDI-TOF identification, molecular assays and antifungal susceptibility testing, can support more precise treatment decisions when available. For high-risk patients, antifungal stewardship means pairing prompt empiric treatment with diagnostic confirmation, source control such as catheter management, and infection-prevention measures in healthcare facilities.